Cost-utility analysis of cariprazine compared to risperidone among patients with negative symptoms of schizophrenia

ConclusionsCariprazine compared to risperidone in the treatment of schizophrenia for patients with negative symptoms provides additional health gain at acceptable costs according to the willingness to pay threshold in Hungary. The findings of the analysis were proven to be robust in the scenario analyses and sensitivity analyses.
Source: Health Policy and Technology - Category: Health Management Source Type: research